↓ Skip to main content

DJ-1/PARK7 Protein

Overview of attention for book
Attention for Chapter 12: Therapeutic Activities of DJ-1 and Its Binding Compounds Against Neurodegenerative Diseases
Altmetric Badge

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Therapeutic Activities of DJ-1 and Its Binding Compounds Against Neurodegenerative Diseases
Chapter number 12
Book title
DJ-1/PARK7 Protein
Published in
Advances in experimental medicine and biology, January 2017
DOI 10.1007/978-981-10-6583-5_12
Pubmed ID
Book ISBNs
978-9-81-106582-8, 978-9-81-106583-5
Authors

Masatoshi Inden, Daijiro Yanagisawa, Masanori Hijioka, Hiroyoshi Ariga, Yoshihisa Kitamura, Inden, Masatoshi, Yanagisawa, Daijiro, Hijioka, Masanori, Ariga, Hiroyoshi, Kitamura, Yoshihisa

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway. Loss-of-function mutations in the gene encoding PARK7/DJ-1 were identified in familial PD. Wild-type DJ-1 acts as an oxidative stress sensor in neural cells. Previously, we identified binding compounds of DJ-1, including UCP0045037/compound A, UCP0054278/compound B, and compound-23 (comp-23), by in silico virtual screening. These compounds prevented oxidative stress-induced dopaminergic neuronal death and restored locomotion defects in animal models of PD. In addition, these binding partners reduced infarct size in cerebral ischemia in rats. The neuroprotective effects of these compounds are lost in DJ-1-knockdown cells and DJ-1-knockout animal. These results suggest that these compounds interact with endogenous DJ-1 and then produce antioxidant and neuroprotective responses in both animal models for PD and cerebral ischemia in rats. This raises the possibility that interaction partners of DJ-1, such as UCP0045037, UCP0054278, and comp-23, may represent a novel dopaminergic neuroprotective drug for the treatment of PD.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 25%
Professor > Associate Professor 2 17%
Researcher 2 17%
Unspecified 1 8%
Lecturer > Senior Lecturer 1 8%
Other 0 0%
Unknown 3 25%
Readers by discipline Count As %
Neuroscience 3 25%
Biochemistry, Genetics and Molecular Biology 2 17%
Unspecified 1 8%
Materials Science 1 8%
Medicine and Dentistry 1 8%
Other 0 0%
Unknown 4 33%